Pramod Bindiganavale Krishnamurthy, MD
Pulmonary Disease · Castro Valley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Eden Medical Center · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Krishnamurthy’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$123,316
Medicare paid this office $123,316 for 473 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 104 | $45,934 | $182 |
| Return visit (30+ min) | 91 | $14,563 | $116 |
| Test to examine how well the lungs exchange gases | 178 | $10,017 | $54 |
| Test to determine lung volumes using sensors | 176 | $9,990 | $54 |
| New patient visit (60+ min) | 41 | $7,549 | $184 |
See all 12 services
| Critical care, first 30-74 minutes | 104 | $45,934 | $182 |
| Return visit (30+ min) | 91 | $14,563 | $116 |
| Test to examine how well the lungs exchange gases | 178 | $10,017 | $54 |
| Test to determine lung volumes using sensors | 176 | $9,990 | $54 |
| New patient visit (60+ min) | 41 | $7,549 | $184 |
| Long return visit (40+ min) | 32 | $6,756 | $165 |
| New patient visit (45+ min) | 40 | $5,904 | $148 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 128 | $5,081 | $37 |
| Short return visit (20+ min) | 36 | $3,460 | $79 |
| Test to measure expiratory airflow and volume | 101 | $2,693 | $26 |
| Critical care, each additional 30 minutes | 14 | $1,388 | $93 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,297 | $118 |
Who their Medicare patients are
473 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 15% · Women 54% · Also on Medicaid 31% · Health risk score 1.66. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Diabetes 40% · Coronary heart disease 37% · COPD 35% · Chronic kidney disease 32% · Heart failure 26% · Atrial fibrillation 24% · Cancer 20% · Depression 18% · Stroke 15% · Dementia 13%.
The office billed $633,931, Medicare allowed $163,427 and paid $123,316; for 1,255 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 473 | 1,255 | 75 | 1.66 | $633,931 | $123,316 |
| 2023 | 420 | 1,112 | 76 | 1.88 | $580,349 | $120,964 |
| 2022 | 453 | 1,278 | 76 | 2.08 | $745,326 | $159,311 |
| 2021 | 256 | 647 | 75 | 2.36 | $445,263 | $94,038 |
| 2020 | 331 | 822 | 74 | 2.50 | $556,477 | $124,348 |
| 2019 | 339 | 848 | 75 | 2.36 | $543,657 | $113,444 |
| 2018 | 188 | 465 | 75 | 1.78 | $235,086 | $52,040 |
| 2017 | 260 | 552 | 73 | 2.00 | $192,158 | $50,776 |
| 2016 | 288 | 523 | 73 | 2.29 | $183,538 | $50,058 |
| 2015 | 234 | 736 | 71 | 2.14 | $229,862 | $60,567 |
| 2014 | 178 | 529 | 72 | 2.21 | $165,379 | $47,355 |
| 2013 | 165 | 518 | 71 | 2.21 | $160,021 | $48,050 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Critical care, first 30-74 minutes | 113 | $48,867 | $189 |
| Return visit (30+ min) | 76 | $12,760 | $116 |
| Test to examine how well the lungs exchange gases | 141 | $8,580 | $58 |
| Test to determine lung volumes using sensors | 131 | $7,631 | $55 |
| Long return visit (40+ min) | 39 | $6,994 | $167 |
| New patient visit (45+ min) | 43 | $6,603 | $154 |
| New patient visit (60+ min) | 30 | $5,784 | $193 |
| Short return visit (20+ min) | 50 | $5,156 | $77 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 126 | $4,971 | $38 |
| Critical care, each additional 30 minutes | 17 | $1,759 | $93 |
| Test to measure expiratory airflow and volume | 49 | $1,373 | $27 |
2022: 13 services
| Critical care, first 30-74 minutes | 169 | $86,567 | $197 |
| Return visit (30+ min) | 69 | $10,704 | $115 |
| Long return visit (40+ min) | 55 | $10,165 | $169 |
| Test to examine how well the lungs exchange gases | 115 | $7,149 | $60 |
| Test to determine lung volumes using sensors | 105 | $5,989 | $55 |
| Short return visit (20+ min) | 48 | $5,614 | $85 |
| New patient visit (45+ min) | 35 | $5,434 | $155 |
| New patient visit (60+ min) | 22 | $4,023 | $183 |
| Critical care, each additional 30 minutes | 30 | $3,002 | $97 |
| Test to measure expiratory airflow and volume | 80 | $2,252 | $27 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 59 | $2,236 | $37 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 14 | $1,719 | $123 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $517 | $20 |
2021: 10 services
| Critical care, first 30-74 minutes | 154 | $70,120 | $201 |
| Critical care, each additional 30 minutes | 32 | $3,217 | $101 |
| Short return visit (20+ min) | 28 | $2,690 | $77 |
| Test to examine how well the lungs exchange gases | 35 | $2,207 | $63 |
| Test to determine lung volumes using sensors | 31 | $1,769 | $57 |
| New patient visit (45+ min) | 11 | $1,645 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,214 | $87 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $875 | $49 |
| Test to measure expiratory airflow and volume | 25 | $758 | $30 |
| Insertion of artery tube for blood sampling or infusion through skin | 14 | $551 | $39 |
2020: 12 services
| Critical care, first 30-74 minutes | 189 | $85,618 | $203 |
| New patient visit (60+ min) | 23 | $4,638 | $202 |
| Critical care, each additional 30 minutes | 38 | $4,271 | $104 |
| Return visit (30+ min) | 30 | $3,788 | $100 |
| Short return visit (20+ min) | 33 | $3,039 | $69 |
| New patient visit (45+ min) | 19 | $2,826 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,155 | $94 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,697 | $131 |
| Test to examine how well the lungs exchange gases | 24 | $1,422 | $59 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 19 | $1,098 | $58 |
| Test to determine lung volumes using sensors | 19 | $1,068 | $56 |
| Test to measure expiratory airflow and volume | 17 | $640 | $38 |
2019: 13 services
| Critical care, first 30-74 minutes | 168 | $66,006 | $193 |
| Short return visit (20+ min) | 52 | $6,476 | $65 |
| New patient visit (60+ min) | 29 | $5,286 | $182 |
| New patient visit (45+ min) | 35 | $5,007 | $143 |
| Return visit (30+ min) | 27 | $3,248 | $98 |
| Long return visit (40+ min) | 21 | $2,828 | $129 |
| Critical care, each additional 30 minutes | 22 | $2,428 | $97 |
| Test to examine how well the lungs exchange gases | 35 | $1,993 | $55 |
| Test to determine lung volumes using sensors | 31 | $1,692 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,656 | $87 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 19 | $1,150 | $61 |
| Test to measure expiratory airflow and volume | 22 | $822 | $36 |
| Short return visit | 14 | $561 | $37 |
2018: 10 services
| Critical care, first 30-74 minutes | 47 | $18,028 | $196 |
| New patient visit (60+ min) | 37 | $6,856 | $185 |
| Short return visit (20+ min) | 53 | $5,397 | $65 |
| New patient visit (45+ min) | 30 | $4,292 | $143 |
| Return visit (30+ min) | 14 | $1,520 | $95 |
| Test to examine how well the lungs exchange gases | 27 | $1,478 | $55 |
| Test to determine lung volumes using sensors | 26 | $1,461 | $56 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $1,120 | $62 |
| Test to measure expiratory airflow and volume | 13 | $474 | $36 |
| Short return visit | 12 | $415 | $35 |
2017: 10 services
| Critical care, first 30-74 minutes | 29 | $13,304 | $196 |
| Short return visit (20+ min) | 110 | $9,921 | $61 |
| New patient visit (45+ min) | 71 | $9,707 | $137 |
| New patient visit (60+ min) | 24 | $4,141 | $173 |
| New patient visit (30+ min) | 25 | $2,225 | $89 |
| Return visit (30+ min) | 20 | $2,049 | $93 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 30 | $1,849 | $60 |
| Short return visit | 34 | $1,368 | $37 |
| Test to determine lung volumes using gas dilution or washout | 27 | $1,095 | $41 |
| Test to examine how well the lungs exchange gases | 31 | $694 | $22 |
2016: 13 services
| Critical care, first 30-74 minutes | 32 | $8,557 | $190 |
| New patient visit (45+ min) | 46 | $6,560 | $143 |
| New patient visit (60+ min) | 26 | $4,618 | $178 |
| Short return visit (20+ min) | 49 | $3,711 | $66 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 16 | $3,040 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,616 | $61 |
| Return visit (30+ min) | 36 | $2,457 | $55 |
| Return visit (30+ min) | 23 | $2,237 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,601 | $89 |
| Short return visit | 14 | $601 | $40 |
| Short return visit (20+ min) | 12 | $510 | $36 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $112 | $10 |
| Test to examine how well the lungs exchange gases | 14 | $101 | $7 |
2015: 17 services
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 41 | $7,340 | $175 |
| Critical care, first 30-74 minutes | 11 | $5,796 | $187 |
| Return visit (30+ min) | 51 | $5,616 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $4,272 | $60 |
| Insertion of indwelling tube for drainage of lung fluid | 16 | $4,055 | $193 |
| New patient visit (60+ min) | 29 | $4,041 | $139 |
| Aspiration of fluid from chest cavity using imaging guidance | 29 | $4,041 | $88 |
| Long return visit (40+ min) | 25 | $3,569 | $89 |
| New patient visit (45+ min) | 27 | $2,937 | $109 |
| Ultrasound of lung airways using an endoscope | 45 | $2,667 | $58 |
| Needle biopsy of lobe of lung using an endoscope, each additional lobe | 19 | $1,512 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,488 | $114 |
| Short return visit (20+ min) | 26 | $1,351 | $42 |
| Review by radiologist of image for drainage of fluid | 14 | $941 | $50 |
| Test to determine lung volumes using sensors | 27 | $288 | $10 |
| Test to examine how well the lungs exchange gases | 29 | $229 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 20 | $228 | $11 |
2014: 15 services
| Critical care, first 30-74 minutes | 15 | $6,490 | $185 |
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 30 | $5,297 | $171 |
| New patient visit (60+ min) | 30 | $4,229 | $141 |
| Long return visit (40+ min) | 29 | $4,132 | $88 |
| Return visit (30+ min) | 40 | $3,843 | $64 |
| Aspiration of fluid from chest cavity using imaging guidance | 26 | $3,363 | $93 |
| Insertion of indwelling tube for drainage of lung fluid | 13 | $2,740 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,399 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,193 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,825 | $83 |
| Ultrasound of lung airways using an endoscope | 30 | $1,800 | $56 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $919 | $32 |
| Short return visit (20+ min) | 15 | $767 | $43 |
| Test to examine how well the lungs exchange gases | 13 | $107 | $8 |
| Test to measure expiratory airflow and volume | 12 | $85 | $7 |
2013: 12 services
| Critical care, first 30-74 minutes | 22 | $9,766 | $181 |
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 36 | $6,885 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $4,657 | $57 |
| Long return visit (40+ min) | 31 | $3,668 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,504 | $83 |
| New patient visit (60+ min) | 22 | $3,016 | $137 |
| Ultrasound of lung airways using an endoscope | 35 | $2,214 | $57 |
| Return visit (30+ min) | 23 | $1,964 | $63 |
| Aspiration of fluid from chest cavity using imaging guidance | 11 | $1,635 | $91 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $474 | $32 |
| Test to determine lung volumes using sensors | 14 | $150 | $11 |
| Test to examine how well the lungs exchange gases | 14 | $111 | $8 |
Medicaid work
$10,001 in 2024
Medicaid paid $10,001 for 98 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 98 | $10,001 |
| 2024 | 98 | 1 | 14 | $10,001 |
| 2023 | 183 | 1 | 14 | $14,718 |
| 2022 | 178 | 1 | 19 | $15,286 |
| 2021 | 135 | 1 | 15 | $25,922 |
| 2020 | 51 | 1 | 15 | $6,176 |
| 2019 | 19 | 1 | 12 | $4,395 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 183 | $14,718 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 178 | $15,286 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 135 | $25,922 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 51 | $6,176 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 19 | $4,395 |
Drugs they prescribed that Part D paid
$467,341
Pharmacies billed $467,341 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
0 generic and 484 brand-name prescriptions · $467,341 in drug cost · 44 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 222 | $212,075 | $955 |
| Breztri Aerosphere | 28 | $26,692 | $953 |
| Breo Ellipta | 38 | $21,762 | $573 |
| Spiriva Respimat | 15 | $11,063 | $738 |
| Arnuity Ellipta | 12 | $9,107 | $759 |
See all 16 drugs
| Trelegy Ellipta | 222 | $212,075 | $955 |
| Breztri Aerosphere | 28 | $26,692 | $953 |
| Breo Ellipta | 38 | $21,762 | $573 |
| Spiriva Respimat | 15 | $11,063 | $738 |
| Arnuity Ellipta | 12 | $9,107 | $759 |
| Advair Hfa | 17 | $5,380 | $316 |
| Fluticasone-Salmeterol | 13 | $2,081 | $160 |
| Albuterol Sulfate Hfa | 57 | $1,678 | $29 |
| Levalbuterol Tartrate Hfa | 15 | $1,458 | $97 |
| Ipratropium | 37 | $1,224 | $33 |
| Montelukast | 31 | $292 | $9 |
| Pantoprazole | 26 | $237 | $9 |
| Prednisone | 42 | $187 | $4 |
| Fluticasone Propionate | 15 | $140 | $9 |
| Azithromycin | 23 | $43 | $2 |
| Furosemide | 11 | $24 | $2 |
Year by year
| 2024 | 786 | 143 | None | 62% | $467,341 |
| 2023 | 762 | 143 | 0% (0) | 65% | $452,256 |
| 2022 | 570 | 116 | 0% (0) | 62% | $307,914 |
| 2021 | 219 | 47 | 0% (0) | 83% | $109,299 |
| 2020 | 239 | 52 | None | 71% | $132,606 |
| 2019 | 216 | 62 | 0% (0) | 63% | $107,078 |
| 2018 | 171 | 65 | 0% (0) | 57% | $41,634 |
| 2017 | 485 | 102 | 0% (0) | 77% | $117,065 |
| 2016 | 183 | 66 | None | 82% | $47,937 |
| 2015 | 190 | 53 | None | 73% | $39,823 |
| 2014 | 105 | 34 | None | 65% | $22,040 |
| 2013 | 139 | 46 | None | 38% | $26,161 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Trelegy Ellipta | 238 | $221,852 | $932 |
| Breo Ellipta | 37 | $21,371 | $578 |
| Arnuity Ellipta | 28 | $15,177 | $542 |
| Spiriva Respimat | 23 | $12,616 | $549 |
| Advair Diskus | 22 | $11,869 | $539 |
| Symbicort | 25 | $10,708 | $428 |
| Advair Hfa | 12 | $5,586 | $465 |
| Fluticasone-Salmeterol | 14 | $3,543 | $253 |
| Albuterol Sulfate Hfa | 50 | $1,701 | $34 |
| Levalbuterol Tartrate Hfa | 12 | $1,579 | $132 |
| Montelukast | 41 | $580 | $14 |
| Pantoprazole | 30 | $537 | $18 |
| Prednisone | 36 | $407 | $11 |
| Azithromycin | 26 | $146 | $6 |
2022: 13 drugs
| Trelegy Ellipta | 175 | $152,399 | $871 |
| Breo Ellipta | 31 | $21,717 | $701 |
| Symbicort | 31 | $13,851 | $447 |
| Arnuity Ellipta | 27 | $10,570 | $391 |
| Advair Diskus | 14 | $6,074 | $434 |
| Spiriva Respimat | 11 | $5,870 | $534 |
| Albuterol Sulfate Hfa | 25 | $1,260 | $50 |
| Pantoprazole | 38 | $432 | $11 |
| Montelukast | 22 | $301 | $14 |
| Prednisone | 33 | $277 | $8 |
| Sulfamethoxazole-Trimethoprim | 19 | $118 | $6 |
| Azithromycin | 20 | $106 | $5 |
| Furosemide | 13 | $42 | $3 |
2021: 4 drugs
| Trelegy Ellipta | 76 | $62,132 | $818 |
| Breo Ellipta | 18 | $17,980 | $999 |
| Arnuity Ellipta | 33 | $10,655 | $323 |
| Albuterol Sulfate Hfa | 21 | $1,028 | $49 |
2020: 4 drugs
| Trelegy Ellipta | 37 | $31,112 | $841 |
| Breo Ellipta | 34 | $25,105 | $738 |
| Arnuity Ellipta | 29 | $7,902 | $272 |
| Albuterol Sulfate Hfa | 24 | $1,427 | $59 |
2019: 4 drugs
| Trelegy Ellipta | 41 | $32,216 | $786 |
| Breo Ellipta | 24 | $18,846 | $785 |
| Arnuity Ellipta | 20 | $3,814 | $191 |
| Fluticasone Propionate | 26 | $642 | $25 |
2018: 5 drugs
| Breo Ellipta | 19 | $8,118 | $427 |
| Anoro Ellipta | 14 | $6,619 | $473 |
| Advair Diskus | 11 | $4,385 | $399 |
| Symbicort | 11 | $3,661 | $333 |
| Fluticasone Propionate | 26 | $364 | $14 |
2017: 15 drugs
| Symbicort | 71 | $21,451 | $302 |
| Advair Diskus | 41 | $15,769 | $385 |
| Spiriva | 26 | $15,394 | $592 |
| Breo Ellipta | 31 | $11,918 | $384 |
| Anoro Ellipta | 29 | $10,252 | $354 |
| Incruse Ellipta | 27 | $8,657 | $321 |
| Spiriva Respimat | 20 | $7,380 | $369 |
| Chantix | 15 | $6,251 | $417 |
| Combivent Respimat | 11 | $3,844 | $349 |
| Proair Hfa | 34 | $1,936 | $57 |
| Ventolin Hfa | 34 | $1,891 | $56 |
| Azelastine | 26 | $1,473 | $57 |
| Fluticasone Propionate | 28 | $305 | $11 |
| Montelukast | 12 | $238 | $20 |
| Prednisone | 15 | $120 | $8 |
2016: 5 drugs
| Anoro Ellipta | 32 | $12,910 | $403 |
| Spiriva | 18 | $7,943 | $441 |
| Symbicort | 19 | $5,224 | $275 |
| Flovent Hfa | 13 | $3,990 | $307 |
| Breo Ellipta | 11 | $3,326 | $302 |
2015: 5 drugs
| Symbicort | 42 | $11,359 | $270 |
| Spiriva | 29 | $9,109 | $314 |
| Combivent Respimat | 13 | $4,210 | $324 |
| Flovent Hfa | 14 | $3,727 | $266 |
| Proair Hfa | 11 | $570 | $52 |
2014: 2 drugs
| Combivent Respimat | 21 | $5,845 | $278 |
| Spiriva | 19 | $5,565 | $293 |
2013: 2 drugs
| Symbicort | 11 | $2,597 | $236 |
| Prednisone | 21 | $103 | $5 |
Money from drug and device companies
$319 in 2025
| 2025 | 7 | 14 | None | $319 |
| 2024 | 1 | 1 | None | $15 |
| 2022 | 1 | 2 | None | $139 |
| 2021 | 1 | 3 | None | $87 |
| 2020 | 1 | 1 | None | $13 |
| 2019 | 1 | 3 | None | $69 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Verona Pharma | Ohtuvayre | $111 | 5 payments
|
| Mallinckrodt Hospital Products | Acthar | $62 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $53 | 2 payments
|
| Philips North America | Vest Therapy Und | $27 | 1 payment
|
| Insmed | Arikayce | $23 | 1 payment
|
| GlaxoSmithKline | Nucala | $22 | 1 payment
|
See all 13 published payments
| Verona Pharma | Meals · 2025-11-21 | Ohtuvayre | $19 |
| Mallinckrodt Hospital Products | Meals · 2025-09-27 | Acthar | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-19 | Ofev | $28 |
| Verona Pharma | Meals · 2025-08-08 | Ohtuvayre | $16 |
| Philips North America | Meals · 2025-07-30 | Vest Therapy Und | $27 |
| Insmed | Meals · 2025-07-16 | Arikayce | $23 |
| Verona Pharma | Meals · 2025-06-05 | Ohtuvayre | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-30 | Ofev | $25 |
| GlaxoSmithKline | Meals · 2025-05-27 | Nucala | $22 |
| Verona Pharma | Meals · 2025-03-18 | Ohtuvayre | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-13 | Airsupra | $21 |
| Verona Pharma | Meals · 2025-02-13 | Ohtuvayre | $27 |
| Mallinckrodt Hospital Products | Meals · 2025-02-05 | Acthar | $34 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $15
| GlaxoSmithKline | Nucala | $15 | 1 payment
|
2022: $139
| Ethicon | Monarch Platform | $139 | 2 payments
|
2021: $87
| Ethicon | Monarch Platform | $87 | 3 payments
|
2020: $13
| Intuitive Surgical | Da Vinci Surgical System | $13 | 1 payment
|
2019: $69
| Intuitive Surgical | Da Vinci Surgical System | $69 | 3 payments
|
Professional record
- NPI
- 1902067085
- Licence
- NY 003134, PA MD446755
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Hospitalist (208M00000X); Student in a training program (390200000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2008-06-20
- NPI last updated
- 2020-06-11
- NPI record certified
- 2020-06-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1860 Pennsylvania Ave, Fairfield, CA, 94533